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ABSTRACT
Opportunistic infection of oligodendrocytes by human JC polyomavirus may result in the development of progressive multifocal
encephalopathy in immunocompromised individuals. Neurotropic JC virus generally harbors reorganized noncoding control
region (NCCR) DNA interspersed on the viral genome between early and late coding genes. By applying 454 sequencing on
NCCRDNA amplified from body fluid samples (urine, plasma, and cerebrospinal fluid [CSF]) from 19 progressive multifocal
leukoencephalopathy (PML) patients, we attempted to reveal the composition of the JC polyomavirus population (the quasispe-
cies, i.e., the whole of the consensus population andminor viral variants) contained in different body compartments and to bet-
ter understand intrapatient viral dissemination. Our data demonstrate that in the CSF of PML patients, the JC viral population is
often a complex mixture composed of multiple viral variants that contribute to the quasispecies. In contrast, urinary JC virus
highly resembled the archetype virus, and urine most often did not contain minor viral variants. It also appeared that archetype
JC virus could sporadically be identified in PML patient brain, although selection of rearranged JC virus DNAwas favored. Com-
parison of the quasispecies from different body compartments within a given patient suggested a strong correlation between the
viral population in plasma and CSF, whereas the viral population shed in urine appeared to be unrelated. In conclusion, it is
shown that the representation of viral DNA in the CSF following the high-level DNA replication in the brain underlying PML has
hitherto beenmuch underestimated. Our data also underscore that the hematogenous route might play a pivotal role in viral
dissemination from or toward the brain.
IMPORTANCE
For the first time, the JC polyomavirus population contained in different body compartments of patients diagnosed with
progressive multifocal encephalopathy has been studied by deep sequencing. Two main findings came out of this work.
First, it became apparent that the complexity of the viral population associated with PML has been highly underestimated
so far, suggestive of a highly dynamic process of reorganization of the noncoding control region of JC polyomavirus in
vivo, mainly in CSF and blood. Second, evidence showing viral dissemination from and/or toward the brain via the hema-
togenous route was provided, confirming a hypothesis that was recently put forward in the field.
JC polyomavirus (JCPyV) is the causative agent for progressivemultifocal leukoencephalopathy (PML), a neurological disor-
der resulting from lytic infection of oligodendrocytes that may
develop in immunosuppressed individuals (e.g., HIV-infected pa-
tients) or under therapy-induced immune suppression (1). Like
other human polyomaviruses, JC virus is a DNA virus with an
5.13-kb double-stranded, circular, supercoiled genome that en-
compasses early and late genes (2). Small t antigen (stAg) and large
T antigen (LTAg) arise from the same primary transcript and are
proteins that are expressed early in the viral cycle and that regulate
viral replication and transcription (3–5). The viral capsid proteins
(VP1, VP2, and VP3) as well as agnoprotein, another regulatory
protein, are expressed only during the late stage of the viral cycle.
Expression of the viral genes is driven by a bidirectional noncod-
ing control region (NCCR) that lies interspersed between the cod-
ing parts of the early and late genes (2). Besides the viral origin of
replication, the NCCR harbors multiple DNA sequence motifs
upon which host cell-specific transcription factors act and, hence,
is key in regulating viral transcription in cells permissive for
JCPyV infection (6, 7).
Infection with JC virus is a prerequisite for PML development.
The majority of humans have experienced JC virus infection (5,
8), often already in childhood, after which the virus can persist
asymptomatically in kidney epithelial cells, urinary tract cells, and
lymphoid organs (5). Several reports have also suggested that
brain tissue is a site for JCPyV latency (9, 10). About one-quarter
of the human population sheds viral DNA in urine, referred to as
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the DNA of archetype virus, for which the NCCR is well-defined
by conserved DNA sequence blocks (domains A to F) (11–13) that
can sporadically display modest genomic variations and can exist
as a mixture of naturally occurring variants (14).
The onset of PML is caused by lytic infection of oligodendro-
cytes by JC virus and can often be diagnosed by magnetic reso-
nance imaging (MRI) and detection of viral DNA in cerebrospinal
fluid (CSF) during disease progression (1, 15). Whereas in PML
cases urinary JCPyV resembles archetype virus, a hallmark of JC
virus DNA isolated from PML patient brain or CSF is the presence
of multiple, often complex, genomic rearrangements in the NCCR
that are hypervariable between patients and are likely to be derived
from the archetype by deletion and duplication events (11, 12, 16,
17). In vitro cell studies indicated that such PML-related rear-
rangements may increase early gene transcription and viral repli-
cation and thus mediate cellular tropism and neuropathogenicity
(18, 19). Whether rearranged JC virus is required for lytic infec-
tion of glial cells or, alternatively, becomes selected as it adapts to
its cellular environment in cells previously infected with archetype
virus is still a matter of debate.
JC virus has been suggested to disseminate from the initial site
of infection via the hematogenous route (5). Besides cell-free JC
virus (20), infected B lymphocytes have been proposed to be a
major carrier enabling JC virus to transmigrate the blood-brain
barrier (BBB) (21–23). The inherent susceptibility of these cells to
genomic rearrangements may also contribute to the neurotropic
transformation of JC virus (22, 24). Unlike blood-borne virus,
urine in which JC virus has been shed likely acts as an important
transmission route within and between human populations (25,
26), but whether it also plays a role in viral dissemination between
body compartments remains poorly understood.
In this study, we have analyzed the JC virus noncoding control
region DNA amplified from different body fluids of PML patients.
By applying deep sequencing (454 pyrosequencing), we attempted
to identify a representative part of the viral population (the qua-
sispecies) contained in different body reservoirs of PML patients
to better understand the nature and genomic diversity of JC virus
associated with PML and to gain insight into viral dissemination
between body compartments. In addition, we wanted to further
investigate the hypothesis, derived from previous work on healthy
subjects, that reorganized minor viral variants present in urine
might be associated with an increased risk for PML develop-
ment (14).
MATERIALS AND METHODS
Specimen collection and JC virus load determination. Body fluid sam-
ples (CSF, plasma/serum, and urine) were collected from 19 PML patients
at the Laboratory of Molecular Medicine and Neuroscience, NINDS, as
part of a Clinical Laboratory Improvement Amendments (CLIA) activity,
using validated and certified assays, through the Centers for Medicare and
Medicaid Services (CMS), U.S. Department of Health and Human Ser-
vices (HHS), and were stored at 80°C until further processing. The
research conducted by the NINDS was reviewed by the Office of Human
Subjects Research Protections (OHSRP), and the research is exempt un-
der 45 CFR 46 101(b) (4) from all 45 CFR part 46 requirements. All PML
patients were diagnosed according to their clinical history, MRI evi-
dence of PML lesions, and the presence of viral DNA in their CSF.
For one patient, one CSF and four urine samples were available, while
for three other patients, one CSF and one or two plasma/serum samples
had been collected. For eight patients, a single CSF sample was available,
and for six patients, a single urine sample was available. From one PML
patient (Table 1, patient 5) three consecutive CSF samples had been col-
lected over 2 months. The JC virus loads from all samples were deter-
mined by species-specific quantitative PCR according to a method de-
scribed earlier (27) and are given in Table 1. Also, the gender of the PML
patients as well as their clinical background is indicated in Table 1.
A DNA template solution containing archetype JC virus NCCR plas-
mid DNA was spiked before PCR amplification with 1% and 2% of a
TABLE 1 Characteristics of PML patients and PML patient samples used in this study
Patient no. Gendera
Clinical
backgroundb
JC virus load(s) (no. of copies/ml)
Urine Plasma CSF
1 M RRMS 5,562,426, 179,375,000, 172,000,000,
225,000,000
69,718
2 F Liver transplant 51,006, 26,912 278,000,000
3 F RRMS 10,812, 4,063 96,438
4 M RRMS 5,035 2,238,800
5 F RRMS 558,967, 756,637, 12,728
6 M RRMS 29,584
7 F MS 15,912
8 F Lymphoma 100,046
9 M RRMS 1,627,025
10 F MS 26,633
11 F MS 181,566
12 M MS 656,020
13 F RRMS 2,501,045
14 F CLL 72,734
15 M MS 43,694,938
16 F MS 94,545,825
17 M MS 189,945,812
18 M RRMS 7,744,225
19 F RRMS 2,804,051
a M, male; F, female.
b MS, Multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis; CLL, chronic lymphocytic leukemia.
Analysis of JC Virus Quasispecies in PML Patients
January 2015 Volume 89 Number 2 jvi.asm.org 1341Journal of Virology
 o
n
 O
ctober 5, 2015 by KU Leuven University Library
http://jvi.asm.org/
D
ow
nloaded from
 
similar plasmid DNA harboring JC virus with a deleted NCCR sequence,
as described earlier (14). These served as control samples.
DNA extraction and amplification of JC virus noncoding control
region DNA. Viral DNA was extracted and concentrated from CSF,
plasma, and urine samples using NucliSENS easyMAG system reagents
(bioMérieux) and eluted in a 25-l final volume. Sample volumes varied
between 0.3 ml and 1 ml. To minimize PCR errors, JC virus NCCR DNA
was amplified in triplicate from the viral DNA using Phusion high-fidelity
master mix (2; New England BioLabs) and sequence-specific Fusion
primers, as described earlier (14). For plasma samples (n  5; viral load
range, 4,063 to 51,006 copies/ml; mean viral load, 19,566 copies/ml), 8l
of extracted DNA was used per PCR replicate, while for urine samples
(n  10; viral load range, 72,734 to 225,000,000 copies/ml; mean viral
load, 92,074,501 copies/ml) and CSF samples (n  15; viral load range,
12,728 to 278,000,000 copies/ml; mean viral load, 19,124,741 copies/ml)
less DNA was used as the template. The number of viral copies per sample
used as the template for PCR (the input copy number) is given in Table 3.
After amplification, triplicate PCR amplicons were pooled and purified,
and the DNA integrity and concentration were determined as described
earlier (14).
Dideoxy DNA sequencing of JC virus noncoding control region
DNA. Purified NCCR amplicons were directly used as the template for
dideoxy DNA sequencing. Template-specific primers (5=-GATTCCTCC
CTATTCAGCACTTTG-3= [forward primer] and 5=-TCCACTCCAGGT
TTTACTAA-3= [reverse primer]) were used for cycle sequencing PCR
using BigDye Terminator (v3.1) cycle sequencing kit reagents (Applied
Biosystems) under the following conditions: 96°C for 1 min, followed by
35 cycles of 96°C for 10 s, 50°C for 5 s, and 60°C for 4 min. Samples were
purified (DyeEx; Qiagen) and run on a 3730xl DNA analyzer (Applied
Biosystems). DNA sequences were analyzed with SeqScape (v2.5) and
Sequencher (v5.0) software.
454 amplicon sequencing of JC virus noncoding control region
DNA. Equimolar amounts of purified NCCR amplicons were subject to
454 pyrosequencing, performed on a GS Junior platform (Roche) at the
VIB Nucleomics Core (http://www.nucleomics.be/; Leuven, Belgium).
Only DNA reads of high quality and containing an intact multiplex iden-
tifier (MID) sequence for sample identification were used for further anal-
ysis. Raw 454 sequencing data have been deposited in the Sequence Read
Archive (SRA) database (accession number SRP043413).
Determination of consensus and minor variant noncoding control
region DNA sequences. The 454 sequencing reads were first segregated
per sample on the basis of the MID introduced in the PCR amplicon. The
sequences were trimmed to remove the low-quality ends as well as 454
sequencing adaptors. Sequences assigned to the same sample were initially
clustered using CD-hit software (28) under default settings, i.e., a se-
quence identity of0.98. Subsequently, NCCR consensus sequences rep-
resenting all generated CD-hit clusters per sample were assembled into
larger clusters using the CLC Main Workbench program (CLC Bio, Den-
mark) to correct for technical errors at homopolymeric DNA stretches.
After clustering and alignment analysis, all reads per sample were re-
mapped against their sample consensus sequences. In all cases,99% of
all sequences, including those attributed to minor viral variants, were
successfully mapped, demonstrating that all minor variant species repre-
senting1% of the viral population were detected by this approach. The
following criteria were used to evaluate the presence of NCCR viral vari-
ants: DNA clusters representing 1% of all reads within a given sample
were not further taken into account, while clusters representing1% of
all reads were considered genuine viral variants. For patients for whom
multiple sample types could be analyzed (i.e., patients 1, 2, and 3), 454
sequences were grouped in forward and reverse reads on the basis of the
direction of their sequenced amplification primer. The forward reads
were used for K-mer-based tree construction (neighbor joining) with the
CLC Genomics Workbench program using a k value of 15 and the Ma-
halanobis distance (29).
Nucleotide sequence accession numbers. JC virus noncoding control
region DNA sequences deviating from the archetype JC virus sequence
(12) were submitted to EMBL/GenBank under accession numbers
LK391951 to LK391961.
RESULTS
JC virus load and dideoxy DNA sequencing of the noncoding
control region DNA. Thirty JC virus DNA-positive samples (10
urine, 5 plasma, and 15 CSF samples) originating from 19 PML
patients were included in this study. The JC viral load from all
PML patient samples was determined by quantitative PCR as de-
scribed before (27), and the viral loads are given in Table 1. For
four PML patients, different body fluid specimens (i.e., either
urine and CSF or plasma and CSF) were analyzed, while for one
other patient, three consecutive CSF samples were available (Table
1). For all remaining PML patients, a single urine or CSF sample
was analyzed.
Following amplification of the JC virus noncoding control re-
gion DNA, its genomic organization was analyzed by dideoxy se-
quencing. The organization of JC virus NCCR DNA amplified
from the urine of PML patients always highly resembled the
organization of the archetype (12) (NCBI accession number
AB038249), with only a single nucleotide variation (i.e., G217A,
according to the numbering described previously [2]) occurring
in 9 out of 10 samples. This polymorphism was previously attrib-
uted to European and Asian JC virus strains (30) and is regularly
seen in urinary JC virus (14). One NCCR consensus sequence
combined a single nucleotide variation (G219A) and a 2-bp dele-
tion (del221-222) (Table 2) previously reported to be occasionally
present in the urine of immunocompetent viral shedders (14).
Analysis of JC virus NCCR DNA amplified from PML patient CSF
and plasma samples revealed a different and more complex pic-
ture. Whereas in 14 out of 15 CSF samples the consensus NCCR
sequence was highly rearranged and unique for each patient, 1
CSF sample (from patient 2; Table 2) displayed the archetype
NCCR sequence. Also, in both plasma/serum samples from the
latter patient, the presence of the archetype NCCR sequence was
confirmed (Table 2). In two additional PML cases (patients 3 and
4), both plasma and CSF contained highly rearranged but identi-
cal consensus NCCR sequences (Table 2). Three consecutive CSF
samples collected within a time frame of 2 months were ana-
lyzed for PML patient 5, and it was shown that the consensus
NCCR sequence remained identical over this period of time. For
one CSF sample (from patient 7), no reliable sequence could be
obtained, indicative of the existence of multiple viral NCCR vari-
ants (quasispecies) present at similar quantities, which was further
confirmed by 454 sequencing.
Detectionofminor JC viral variants by 454 sequencing of the
noncoding control region DNA. To identify possible minor viral
variants and, thus, to be able to characterize a representative part
of the viral population (the JC virus quasispecies) contained in the
different body compartments of PML patients, 454 sequencing
was applied to the above-mentioned samples as well as plasmid
control samples. Amplification of JC virus NCCR DNA was per-
formed in triplicate to enhance the likelihood of amplifying viral
variants present at low levels as well as to minimize errors possibly
introduced by PCR. The highly varying JC viral load assigned to
the samples (mean, 40,257,132 copies/ml; minimum, 4,063 cop-
ies/ml; maximum, 278,000,000 copies/ml; Table 1) was also taken
into account. Hence, for samples with relatively low viral copy
Van Loy et al.
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numbers, a maximal input of viral DNA was used for PCR, while
for samples with high viral copy numbers, less DNA was required
to introduce a representative amount of viral copies for deep se-
quencing. The number of viral copies per sample used in the ex-
perimental setup is given in Table 3. Plasmid DNA samples har-
boring archetype JC virus NCCR with or without a predefined
deletion of domain D were processed as described elsewhere (14),
and the accuracy of detecting DNA deletions in the JCPyV NCCR
by our 454 sequencing approach was confirmed (data not shown).
454 amplicon sequencing resulted in 92,169 high-quality JC
virus NCCR sequences (reads) divided over 30 PML samples. For
each sample, an average of 3,072 reads (maximum, 6,195 reads;
minimum, 160 reads; median, 2,851 reads; Table 3) was used for
further analysis. On the basis of the ratio of the number of reads
and the input viral copy number per sample, a sampling size was
calculated. Since this sampling size was100 for all samples (min-
imum, 0.01; maximum, 47.69), no redundancy (i.e., sequencing
of the same viral copy multiple times) was introduced in our data
set (Table 3), and thus, all sequences obtained were considered to
originate from a unique viral copy. To allow reliable determina-
tion of JC virus NCCR minor variants representing 1% of the
viral population, only those samples for which1,000 reads were
generated were used. This means that minorities representing
1% of the viral population would be detected by the use of at
least 10 DNA sequences. As a consequence, one plasma sample
(from patient 4) and two CSF samples (from patients 4 and 12)
were withdrawn from further analysis (Tables 2 and 3).
For all samples, the NCCR consensus sequence, as well as the
NCCR sequences of the minor viral variants contributing to the
quasispecies, were determined from the 454 sequencing data. To
do so, sequences attributed to each sample were initially clustered
utilizing CD-hit software under default settings (28), and NCCR
sequences representing all clusters were further analyzed as de-
scribed above. In all cases, the consensus NCCR sequence ob-
tained by 454 sequencing agreed with the sequence obtained by
dideoxy sequencing. A discrepancy between urinary and CSF/
plasma NCCR sequences became immediately apparent. Whereas
the sequences of the vast majority of reads obtained for urine
samples very much resembled the archetype NCCR sequence, se-
quences originating from CSF or plasma often appeared to be a
mixture of highly diverse sequences whose organization did not
share the organization of the archetype sequence. JC virus NCCR
minor variants were detected in 11 out of 13 CSF specimens and all
plasma/serum samples (n 4) but in only 2 out of 10 urine sam-
ples. In addition, whereas in urine only one minor viral variant
contributed to the quasispecies, the JC viruses in CSF appeared to
be a highly complex mixture of natural variants. In those samples
in which more than one rearranged NCCR sequence was identi-
fied, it appeared that longer forms of the NCCR coexisted with
shorter forms that were derived therefrom by a single deletion, as
TABLE 2 Consensus and minor variant JC virus NCCR organization in PML patients
Patient no. Matrix
Consensus NCCR
sequencea
Presence of minor
variantb
Minor variant species
(% of isolates)c
1 Urine (n 4) AR (G217A) n None
1 CSF RR n None
2 Plasma (n 2) AR (G217A) y del115-183 (7)
2 CSF AR (G217A) y del115-183 (12)
3 Plasma (n 2) RR y del63-136 (2)
3 CSF RR y del63-136 (3)
4 Plasma RR ND ND
4 CSF RR ND ND
5 CSF RR y del64-168 (23)
5 CSF RR y del64-168 (23)
5 CSF RR n None
6 CSF RR y del61-126 (3)
7 CSF ND y Highly diverse
8 CSF RR y del192-274 (2)	 del149-250 (11)
9 CSF RR y del63-139 (7)
10 CSF RR y Various (n 6) deletions and
rearrangements (2–8)
11 CSF RR y Highly diverse
12 CSF RR ND ND
13 CSF RR y del61-133 (8)
14 Urine AR (G217A) n None
15 Urine AR (G217A) y del165-192 (2)
16 Urine AR (G217A) n None
17 Urine AR (G219A	 del221-222) y ins222 (21 ntd) (2)
18 Urine AR (G217A) n None
19 Urine AR (G217A) n None
a AR, archetype; RR, rearranged; G217A, polymorphism at position 217; G219A, polymorphism at position 219; del, deletion.
b y, yes [a minor variant(s) was present]; n, no (a minor variant was not present); ND, not determined.
c The numbering of the deletion (del) or insertion (ins) is relative to that of the consensus sequence of the corresponding sample. The percentage of samples in which the minor
variants were detected is given in parentheses. For simplicity, patients 7 and 11 are defined as highly diverse since up to 10 viral variants contributed to the quasispecies.
d nt, nucleotides.
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exemplified by the NCCR variants detected in patient 10 (Fig. 1).
An overview of the NCCR quasispecies identified in PML patient
body fluid samples is presented in Table 2.
A remarkable feature of JC virus quasispecies in PML cases was
the correlation between the viral population identified in CSF and
the one identified in plasma/serum, since both the consensus
NCCR sequence and the NCCR sequences of the minority vari-
ants from both body compartments from the same patients were
identical (Table 2; Fig. 2). In contrast, for one PML patient (pa-
tient 1) for which urine and CSF were examined, both body com-
partments contained clearly distinct viral populations (Table 2).
DISCUSSION
Detailed analysis of the JC virus DNA population contained in
different body compartments of PML patients might shed light on
viral dissemination within the patient and further characterizes
the viral strains associated with PML. In this study, 454 sequenc-
ing was used to analyze the noncoding control region DNA in 30
JC virus-positive body fluid samples (CSF, plasma/serum, and
urine) from PML patients. Unlike earlier studies in which the
consensus NCCR sequence in different PML patient sample types
was determined by dideoxy DNA sequencing (11), we aimed at
additionally identifying the minor viral variants contributing to
the JC virus quasispecies. Moreover, our sample set allowed, at
least in a subgroup of patients, comparison of the quasispecies
between body fluids within a patient and, thus, to learn about viral
dissemination.
In a current understanding, acquisition of neurotropic JC
virus occurs at some point during PML development and often
leads to the presence of a highly rearranged JC virus NCCR in
CSF at the time of or following diagnosis. In vitro cell studies
indicated that such rearrangements enhance early viral gene
expression and support higher replication rates in glial cells; as
a consequence, they increase the cytopathology (18). A notable
feature of PML-associated rearranged JCPyV is the total or
partial deletion of domain D of the noncoding control region
(11, 17). In the majority of the PML patient CSF and plasma
samples described here, domain D was also highly affected.
However, archetype NCCR was identified in both the CSF and
plasma of PML patient 2, a patient that was sampled 6 months
after a liver transplant due to hepatitis C cirrhosis. The CSF
sample of this patient had an extremely high viral load of
278,000,000 copies/ml, and in addition, 12% of this viral
population contained a DNA deletion of domain D and part of
domain E. Although it is not trivial to interpret to what extent
both variants contributed to the high JC viral load in CSF, the
fact that the archetype represented the vast majority of the
virus detected in CSF indicates that archetype JC virus can be
found in vivo in a predominantly glial cell environment. Re-
cently, an unusual archetype organization of the JC virus
NCCR has also been identified in the CSF of two PML patients
with long-term HIV-1 infection and one HIV-1-positive pa-
tient diagnosed with classical PML (16, 31). In addition, in vitro
studies showed that NCCR rearrangement is not required per se
for activity in glial cells (32, 33), although it might still enhance
neurovirulence (18). Taken together, our data support the
novel notion that PML can occasionally be associated with
archetype JC virus, although in the majority of cases, rearrange-
ment of the NCCR is still favored.
The majority of the human population becomes infected
with JC virus, after which the virus can persist lifelong without
apparent symptoms. Multiple sites of JC virus latency exist,
including kidney epithelial cells, the urinary tract, lymphoid
tissue, and the brain (1, 9, 10, 34–36), whereas bone marrow
and B lymphocytes originating therefrom have been suggested
to be potential sites for JC virus neurotropic transformation
(21, 24, 35) due to their inherent susceptibility to DNA rear-
rangement that might favor the emergence of rearranged
JCPyV. Both virus-infected lymphocytes and cell-free virus
have been suggested to participate in viral dissemination by
crossing the blood-brain barrier (20, 23, 35, 37), whereas cell-
mediated viral carriage might have clinical relevance in pa-
tients subject to increased peripheral mobilization of hematopoi-
etic progenitor (CD34	) cells due to continued natalizumab
treatment (34). Two of the PML patients that we examined
were of particular interest since both plasma and CSF samples
could be analyzed. Our data support a route of JC virus dissem-
ination between blood and the central nervous system since
both the consensus NCCR DNA sequence and the sequence of
the quasispecies of virus from those body compartments cor-
related well. In contrast, the urinary JC virus population ap-
peared to exist as an independent viral population. This phe-
nomenon has been appreciated for some time, but this study
TABLE 3 Number of NCCR sequences per sample retrieved by 454
sequencing
Patient no. No. of reads
JCPyV load
(no. of copies/ml)
Input copy
no.a
Sampling
sizeb
1 2,715 69,718 50,196 5.41
1 3,074 5,562,426 2,669,964 0.12
1 3,337 179,375,000 43,050,000 0.01
1 3,500 172,000,000 41,280,000 0.01
1 2,588 225,000,000 54,000,000 0.01
2 2,512 278,000,000 33,360,000 0.01
2 1,511 51,006 14,690 10.29
2 1,390 26,912 7,750 17.94
3 6,195 96,438 46,290 13.38
3 1,932 10,812 10,380 18.61
3 1,860 4,063 3,900 47.69
4 160 5,035 1,450 11.03
4 622 2,238,800 1,074,624 0.06
5 1,677 558,967 536,608 0.31
5 1,567 756,637 453,982 0.35
5 1,453 12,728 12,219 11.89
6 3,265 29,584 14,200 22.99
7 4,839 15,912 15,276 31.68
8 3,515 100,046 96,044 3.66
9 3,982 1,627,025 488,108 0.82
10 2,163 26,633 25,568 8.46
11 1,810 181,566 174,303 1.04
12 809 656,020 472,334 0.17
13 2,987 2,501,045 1,500,627 0.20
14 5,931 72,734 34,912 16.99
15 4,771 43,694,938 10,486,785 0.05
16 5,196 94,545,825 22,690,998 0.02
17 5,834 189,945,812 45,586,995 0.01
18 5,583 7,744,225 1,858,614 0.30
19 5,391 2,804,051 1,345,944 0.40
a The number of viral copies used for triplicate amplification of the JCPyV NCCR.
b Sampling size is defined as [(number of reads/input copy number) 100].
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now provides concrete evidence for it in a series of PML
samples.
Although matching urine and CSF samples could be examined
for only one PML patient, the JC virus NCCR DNA present in
urine did not resemble the highly rearranged virus DNA generally
found in CSF. Recently, we also showed that JCPyV NCCR quasi-
species reminiscent of those from PML patients were occasionally
present in the urine of healthy viral shedders (14) and hypothe-
sized that this might be reflective of the situation in other body
reservoirs. The current data, however, clearly indicate that there is
no correlation between urinary and CSF/plasma JCPyV and thus
exclude quasispecies analysis in urine as a factor predictive of PML
development. The independence between urinary and nonurinary
JC virus has also been observed when examining the correlation
between mutations in the major capsid protein VP1 in urine and
nonurine samples from PML patients, since VP1 mutations pres-
ent in virus from blood and/or CSF were absent in virus from
urine (11).
A major advantage of deep sequencing is its ability to pro-
vide an in-depth analysis of the viral population. Whereas JC
virus strains from PML cases are often referred to as homoge-
neous populations, we showed that the JC viral population in
CSF and/or blood of PML patients most often exists as a mix-
ture of naturally occurring viral variants, with in some cases up
to 10 JC viral variants harboring diverse noncoding control
region DNA sequences. Similar observations were previously
made by colony sequencing of virus in the CSF of a few PML
cases (17), although the colony sequencing technology is much
less sensitive than deep sequencing in detecting minor variants,
since many fewer DNA sequences are generated compared to
the number generated by deep sequencing, and, hence, colony
sequencing is likely to underappreciate the true complexity of
the viral population.
Despite the high variability of reorganization of the NCCR
between different patients, multiple viral variants within a single
sample could often be derived from each other by single deletion
or duplication events, reflective of a process throughout which the
virus continuously adapts to its cellular environment. In contrast,
the JC virus population in urine appeared to be stable, and in the
urine viral population, archetype virus was continuously selected
and additional minor NCCR variants were detected only sporad-
ically (i.e., in 2 out of 10 samples analyzed). The sequences of these
minor variants deviated from the consensus NCCR sequence by
means of a single deletion, as has previously been observed in the
urine of healthy subjects (14).
In conclusion, by applying deep sequencing to JC virus non-
coding control region DNA isolated from different body reser-
voirs of PML patients, we have shown that JC virus can appear as
a quasispecies that is shared between CSF and plasma within a
single patient but is unrelated to urinary JC virus. Due to this
intimate correlation between virus in CSF and plasma, our find-
FIG 1 JC virus NCCR quasispecies identified in CSF from PML patient 10. Both the consensus NCCR sequence and the sequence of minor variants are
schematically shown and compared to the archetype (AR) sequence. The amount of each variant present as a percentage of the total quasispecies is indicated on
the right. Numbers in parentheses indicate the original nucleotide sequence position in the archetype sequence.
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ings seem to further support the clinical relevance of JC virus
viremia.
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